Loading clinical trials...
Loading clinical trials...
Composite Inflammatory Parameters Ratios Enforce the Role of CRP for Monitoring Ulcerative Colitis Disease Activity
Inflammatory Bowel Disease (IBD) is a chronic, recurrent condition marked by disturbed levels of various hematological inflammatory cells and a deregulated immune environment. While C-reactive protein (CRP) is a key acute-phase reactant, its high levels can persist even after inflammation subsides. Other simple, cost-effective ratios, such as the Neutrophil-to-Lymphocyte Ratio (NLR), the Platelet-to-Lymphocyte Ratio (PLR), and Albumin-related ratios, also serve as promising, reproducible markers of systemic inflammation reflecting both immune status and nutrition. This study's objective is to evaluate the diagnostic performance of these various hematological inflammatory cellular components and CRP-related ratios (like the CAR) as predictors for Ulcerative Colitis (UC) disease severity, using colonoscopic and microscopic findings as the gold standard for comparison.
Age
18 - 45 years
Sex
ALL
Healthy Volunteers
No
Alexandria Faculty of medicine
Alexandria, El Alexandria, Egypt
Start Date
September 15, 2025
Primary Completion Date
November 25, 2025
Completion Date
December 1, 2025
Last Updated
January 21, 2026
80
ACTUAL participants
C-Reactive Protein measuring CRP
DIAGNOSTIC_TEST
CRP to Albumin Ratio
DIAGNOSTIC_TEST
Lead Sponsor
Benha University
NCT07271069
NCT06975722
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07185009